95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Cynthia Ménard1*†
Inmaculada Navarro-Domenech2†
Zhihu (Amy) Liu2
Lisa Joseph2Maroie Barkati1
Alejandro Berlin2
Guila Delouya1
Daniel Taussky1Marie-Claude Beauchemin1Benedicte Nicolas1
Samuel Kadoury3
Alexandra Rink2
Srinivas Raman2Aravindhan Sundaramurthy2
Robert Weersink2Dominic Beliveau-Nadeau1Joelle Helou2
Peter Chung2- 1Radiation Oncology, Centre Hospitaliser de l’Université de Montréal (CHUM), Montreal, QC, Canada
- 2Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
- 3Radiation Oncology, Polytechnique Montreal, Montreal, QC, Canada
A Corrigendum on
MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer
By Ménard C, Navarro-Domenech I, Liu Z(A), Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin M-C, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J and Chung P (2022) Front. Oncol. 12:971344. doi: 10.3389/fonc.2022.971344
In the published article, there was an error in the author list. In the published manuscript the author list appears erroneously: Cynthia Ménard¹*†, Inmaculada Navarro-Domenech²†, Zhihu (Amy) Liu², Lisa Joseph², Maroie Barkati¹, Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹, Marie-Claude Beauchemin¹, Benedicte Nicolas¹, Samuel Kadoury³, Alexandra Rink², Srinivas Raman², Aravindhan Sundaramurthy², Robert Weersink², Dominic Beliveau-Nadeau¹, Joelle Helou², and Peter Chung² on behalf of NIKE.
The corrected author list is as appears below.
Cynthia Ménard¹*†, Inmaculada Navarro-Domenech²†, Zhihu (Amy) Liu², Lisa Joseph², Maroie Barkati¹, Alejandro Berlin², Guila Delouya¹, Daniel Taussky¹, Marie-Claude Beauchemin¹, Benedicte Nicolas¹, Samuel Kadoury³, Alexandra Rink², Srinivas Raman², Aravindhan Sundaramurthy², Robert Weersink², Dominic Beliveau-Nadeau¹, Joelle Helou², and Peter Chung²
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: prostate cancer, brachytherapy, salvage, radiotherapy, magnetic resonance imaging
Citation: Ménard C, Navarro-Domenech I, Liu Z(A), Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin M-C, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J and Chung P (2022) Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer. Front. Oncol. 12:1084708. doi: 10.3389/fonc.2022.1084708
Received: 30 October 2022; Accepted: 04 November 2022;
Published: 17 November 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Ménard, Navarro-Domenech, Liu, Joseph, Barkati, Berlin, Delouya, Taussky, Beauchemin, Nicolas, Kadoury, Rink, Raman, Sundaramurthy, Weersink, Beliveau-Nadeau, Helou and Chung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cynthia Ménard, Q3ludGhpYS5NZW5hcmRAdW1vbnRyZWFsLmNh
†These authors have contributed equally to this work and share first authorship